ABRAXANE
Drug
Celgene Corporation
Total Payments
$263,478
Transactions
5
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $263,478 | 5 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $263,478 | 5 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Understanding Therapeutic Efficacy and Resistance in Patients with Metastatic Pancreatic Ductal Adenocarcinoma | Celgene Corporation | $120,151 | 0 |
| A PHASE II TRIAL OF NAB-PACLITAXEL PLUS CISPLATIN PLUS GEMCITABINE IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA | Celgene Corporation | $74,316 | 0 |
| BrUOG P318: FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial | Celgene Corporation | $46,464 | 0 |
| Phase II study of Abraxane and gemcitabine in patients with advanced adenocarcinoma non-small cell lung cancer progressing after first-line platinum-based chemotherapy | Celgene Corporation | $22,546 | 0 |
Top Doctors Receiving Payments for ABRAXANE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Scottsdale, AZ | $263,478 | 5 |
Ad
Manufacturing Companies
- Celgene Corporation $263,478
Product Information
- Type Drug
- Total Payments $263,478
- Total Doctors 0
- Transactions 5
About ABRAXANE
ABRAXANE is a drug associated with $263,478 in payments to 0 healthcare providers, recorded across 5 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2022 to 2022. In 2022, $263,478 was paid across 5 transactions to 0 doctors.
The most common payment nature for ABRAXANE is "Unspecified" ($263,478, 100.0% of total).
ABRAXANE is associated with 4 research studies, including "Understanding Therapeutic Efficacy and Resistance in Patients with Metastatic Pancreatic Ductal Adenocarcinoma" ($120,151).